Cross-talk between EGFR and IGF-1R pathways promotes resistance to EGFR TKIs and monoclonal antibodies for EGFR and the upregulation of IGF-1R in NSCLC patients, inducing EGFR TKI resistance [52,53,54]. Here, EGFR is linked to non-small cell lung carcinoma.